ArticleScientific reports2016
Interferon-γ and Tumor Necrosis Factor-α Polarize Bone Marrow Stromal Cells Uniformly to a Th1 Phenotype.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 80 citations in OpenAlex.
- Serum IFN-γ Predicts the Therapeutic Effect of Mesenchymal Stem Cells Transplantation in Systemic Lupus Erythematosus Patients.Stem cells translational medicine · 2017Trial
- A gE/gI/US9-triple deletion inactivated vaccine provides complete protection against emerging PRV variant infection.BMC veterinary research · 2026Article
- IFNγ and TNFα optimize salivary gland mesenchymal stromal cells: an alternative to marrow- and adipose-MSCs for radiation xerostomia.Regenerative therapy · 2025Article
- In vitro cytokine response of circulating mononuclear cells from healthy dogs to stage-specific antigens of Angiostrongylus vasorum.BMC veterinary research · 2025Article
- Establishment and validation of red fox (vulpes vulpes) airway epithelial cell cultures at the air-liquid-interface.Scientific reports · 2025Article
- Matrix stiffness and viscoelasticity influence human mesenchymal stem cell immunomodulation.Mechanobiology in medicine · 2025Article
- In situ licensing of mesenchymal stem cell immunomodulatory function via BMP-2 induced developmental process.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Mesenchymal stem cells - the secret agents of cancer immunotherapy: Promises, challenges, and surprising twists.Oncotarget · 2024Review
- Translational potential of mesenchymal stem cells in regenerative therapies for human diseases: challenges and opportunities.Stem cell research & therapy · 2024Review
- Mesenchymal stromal cell derived extracellular vesicles as a therapeutic tool: immune regulation, MSC priming, and applications to SLE.Frontiers in immunology · 2024Review
- Inflammatory Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma: Transcriptional Signature and In Vitro Modeling.Cancers · 2023Article
- Pretreated Mesenchymal Stem Cells and Their Secretome: Enhanced Immunotherapeutic Strategies.International journal of molecular sciences · 2023Review
- The role of TNF-α in the fate regulation and functional reprogramming of mesenchymal stem cells in an inflammatory microenvironment.Frontiers in immunology · 2023Review
- Effects of Stromal Cell Conditioned Medium and Antipurinergic Treatment on Macrophage Phenotype.Tissue engineering. Part C, Methods · 2022Article
- Enforced mesenchymal stem cell tissue colonization counteracts immunopathology.NPJ Regenerative medicine · 2022Article
- Article
- Mesenchymal stem cells empower T cells in the lymph nodes via MCP-1/PD-L1 axis.Cell death & disease · 2022Article
- Article
- Mesenchymal Stromal Cell Therapy in Spinal Cord Injury: Mechanisms and Prospects.Frontiers in cellular neuroscience · 2022Review
- Differential and sequential immunomodulatory role of neutrophils and Ly6CEmerging microbes & infections · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
Activated T cells polarize mesenchymal stromal cells (MSCs) to a proinflammatory Th1 phenotype which likely has an important role in amplifying the immune response in the tumor microenvironment. We investigated the role of interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α), two factors produced by activated T cells, in MSC polarization. Gene expression and culture supernatant analysis showed that TNF-α and IFN-γ stimulated MSCs expressed distinct sets of proinflammatory factors. The combination of IFN-γ and TNF-α was synergistic and induced a transcriptome most similar to that found in MSCs stimulated with activated T cells and similar to that found in the inflamed tumor microenvironment; a Th1 phenotype with the expression of the immunosuppressive factors IL-4, IL-10, CD274/PD-L1 and indoleamine 2,3 dioxygenase (IDO). Single cell qRT-PCR analysis showed that the combination of IFN-γ and TNF-α polarized uniformly to this phenotype. The combination of IFN-γ and TNF-α results in the synergist uniform polarization of MSCs toward a primarily Th1 phenotype. The stimulation of MSCs by IFN-γ and TNF-α released from activated tumor infiltrating T cells is likely responsible for the production of many factors that characterize the tumor microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.